Apogee Therapeutics, Inc.
APGE
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.4B
$135.07
▲ 0.00%
P/E
-31.12
Mkt Cap
$8.4B
52-Wk Range
$35.39–$135.09
52-Week Range
$35.39 - $135.09
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 251.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Extended half-life monoclonal antibody technology enabling less frequent dosing
- Focused pipeline targeting high-prevalence inflammatory diseases with large addressable markets
- Subcutaneous administration route improving patient convenience versus intravenous alternatives
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Clinical trial progression of APG777 in atopic dermatitis with potential for market approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+62.7% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying APGE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$1.14 vs -$1.07 consensus (-6.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
12 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
75%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 12, 2026
vs Industry
How APGE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related